Frost & Sullivan Independent Equity Research

BiolineRx. An Opportunity to Invest in the Development of Unique Cancer Treatment Technologies

bioline

Company: BioLineRx        

Sector: Pharmaceuticals

Report type: Initiation of Coverage

For all past reports click here

Published on: July 20th 2017

View Fullscreen

Download full report